Tau and amyloid beta (Aβ) are the prime suspects for driving pathology in Alzheimer's
disease (AD) and, as such, have become the focus of therapeutic development. Recent …

Treatments for Alzheimer's disease (AD) directed against the prominent amyloid plaque
neuropathology are yet to be proved effective despite many phase 3 clinical trials. There are …

Ischemic stroke represents a significant danger to human beings, especially the elderly.
Interventions are only available to remove the clot, and the mechanism of neuronal death …

Converging evidence continues to point towards Tau aggregation and pathology formation
as central events in the pathogenesis of Alzheimer's disease and other Tauopathies …

Functional failure of tau contributes to age-dependent, iron-mediated neurotoxicity, and as
iron accumulates in ischemic stroke tissue, we hypothesized that tau failure may exaggerate …

Perturbations in iron homeostasis and iron accumulation feature in several
neurodegenerative disorders including Alzheimer's disease (AD), Parkinson's disease (PD) …

Tau is a microtubule-associated protein that has a role in stabilizing neuronal microtubules
and thus in promoting axonal outgrowth. Structurally, tau is a natively unfolded protein, is …

Brain iron homeostasis is increasingly recognized as a potential target for the development
of drug therapies for aging‐related disorders. Dysregulation of iron metabolism associated …

Tau protein plays a critical role in the assembly, stabilization, and modulation of
microtubules, which are important for the normal function of neurons and the brain. In …

Over 30 million people suffer from the consequences of ischemic stroke. The precise
molecular mechanism of neuronal damage during ischemic stroke remains unclear; …